Aclaris Therapeutics, Inc. (ACRS)

Last Price:  

Company Description

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $4.23M
Net Income (Most Recent Fiscal Year) $-161.35M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 7.25
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 1.16
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -1597.87%
Net Margin (Trailing 12 Months) -1490.64%
Return on Equity (Trailing 12 Months) -99.67%
Return on Assets (Trailing 12 Months) -61.01%
Current Ratio (Most Recent Fiscal Quarter) 4.01
Quick Ratio (Most Recent Fiscal Quarter) 4.01
Debt to Common Equity (Most Recent Fiscal Quarter) 0.18
Inventory Turnover (Trailing 12 Months) 89.02
Book Value per Share (Most Recent Fiscal Quarter) $1.69
Earnings per Share (Most Recent Fiscal Quarter) $-0.36
Earnings per Share (Most Recent Fiscal Year) $-2.25
Diluted Earnings per Share (Trailing 12 Months) $-3.37
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 41.87M
Free Float 35.67M
Market Capitalization $67.82M
Average Volume (Last 20 Days) 1.03M
Beta (Past 60 Months) 1.16
Percentage Held By Insiders (Latest Annual Proxy Report) 14.80%
Percentage Held By Institutions (Latest 13F Reports) 81.27%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%